Daphne Karydas
Director at Mineralys Therapeutics, Inc. (MLYS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $926K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 3,0006,200 held (−33%) | $28.58 | $86K | -18.2% |
| Jun 17SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 3,0006,200 held (−33%) | $25.00 | $75K | -6.5% |
| Apr 2SEC | MLYSMineralys Therapeutics, Inc. | Sell Plan | 3,0006,200 held (−33%) | $25.00 | $75K | -6.5% |
| Nov 13SEC | MLYSMineralys Therapeutics, Inc. | Sell | 10,1154,885 held (−67%) | $45.81 | $463K | -49.0% |
| Nov 13SEC | MLYSMineralys Therapeutics, Inc. | Sell | 4,885 | $46.36 | $226K | -49.6% |
- Sell
Director Daphne Karydas sold $86K of MLYS at $28.58 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Daphne Karydas sold $75K of MLYS at $25.00 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Daphne Karydas sold $75K of MLYS at $25.00 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Daphne Karydas sold $463K of MLYS at $45.81 — cuts the stake by 67%.